Privium Fund Management B.V. Krystal Biotech, Inc. Transaction History
Privium Fund Management B.V.
- $354 Million
- Q2 2024
A detailed history of Privium Fund Management B.V. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 6,420 shares of KRYS stock, worth $1.13 Million. This represents 0.33% of its overall portfolio holdings.
Number of Shares
6,420
Previous 4,500
42.67%
Holding current value
$1.13 Million
Previous $800,000
47.25%
% of portfolio
0.33%
Previous 0.24%
Shares
8 transactions
Others Institutions Holding KRYS
# of Institutions
274Shares Held
24.9MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$696 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$506 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$429 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$235 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$180 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.52B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...